Holen Sie sich die Stockscreener-App
0.00
100.00%
-11.49
Schlusskurs vom Vortag:
$11.49
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$11.50
52-Wochen-Spanne:
$0.00
$30.45
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
Firmenname
Newamsterdam Pharma Company N V
Sektor
Branche
Telefon
31 35 206 2971
Adresse
Gooimeer 2-35, Naarden
Compare NAMSW vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMSW
Newamsterdam Pharma Company N V
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.11 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
169.55 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
998.93 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
194.28 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company N V Aktie (NAMSW) Neueste Nachrichten
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK
NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - Investing.com
NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam Pharma Company N.V. - Reuters
NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - Kalkine Media
NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - kalkine.ca
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Barchart.com
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate plans Nasdaq share sale over 90 days - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate readies Nasdaq share sale - Stock Titan
NewAmsterdam (NAMSW) Shares: Moves 3.19% Higher to $16.51; Level Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingFactor Momentum - vinanet.vn
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Acceleration Picks - vinanet.vn
NewAmsterdam (NAMSW) Shares: Shows Minimal Net Change at $16.00 in Latest Trading; Trading Range: Support at $15.20 and Resistance at $16.80 Frame the Range in the Latest SessionSingle Stock ETF - vinanet.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Plunging Sales And Deepening Losses - Sahm
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Bank of America Corp DE - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB - MarketBeat
NewAmsterdam Pharma Warrant (NAMSW) Flat at $16.72 as Range-Bound Trading PersistsVolume Breadth - vinanet.vn
NewAmsterdam Pharma Warrant (NAMSW) Holds Ground at $16.72 as Trading Range TightensAAII Neutral - vinanet.vn
NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal - Stock Titan
NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer - Stock Titan
Newamsterdam Pharma Company N.V. Announces Executive Changes - marketscreener.com
NewAmsterdam Pharma (NAMS) Slips 0.30% to $26.59, Holds Within Established RangeIV Rank - Vinanet
NewAmsterdam Pharma (NAMS) Edges Higher to $27.83 as Range-Bound Trading PersistsBreakout Stock Alerts - vinanet.vn
Did NewAmsterdam Pharma’s (NAMS) Sharp Revenue Drop and Wider Loss Just Shift Its Investment Narrative? - webull.com
How Newamsterdam Pharma Company N.v. (NAMS) Affects Rotational Strategy Timing - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring an 83.24% Potential Upside in Biotech - DirectorsTalk Interviews
HC Wainwright Issues Pessimistic Outlook for NAMS Earnings - MarketBeat
Equities Analysts Offer Predictions for NAMS FY2027 Earnings - MarketBeat
Three New Hires Receive Stock Awards With Up to 4-Year Vesting - Stock Titan
NewAmsterdam Pharma grants 28,000 inducement share options at $27.79 to new hires - Bitget
(NAMSW) Volatility Zones as Tactical Triggers - Stock Traders Daily
FMR LLC and Abigail Johnson report 10.3M-share Pharma Company NV (NAMS) stake - Stock Titan
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears - NewsBreak: Local News & Alerts
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Company N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - The Manila Times
Finanzdaten der Newamsterdam Pharma Company N V-Aktie (NAMSW)
Es liegen keine Finanzdaten für Newamsterdam Pharma Company N V (NAMSW) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
Kapitalisierung:
|
Volumen (24h):